Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL [Phase 3]
A Phase III clinical trial evaluating HMPL-760 plus R-GemOx versus placebo plus R-GemOx for relapsed/refractory diffuse large B-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the combination therapy DZD8586 in patients with Diffuse Large B-Cell Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies [Phase 1, Phase 2]
Phase 1/2 trial update for SHB-02-CD19, a novel CD19-directed CAR-T therapy, in CD19-expressing B-cell malignancies; recruitment not yet sta…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating memory-enriched T cells following stem cell transplantation for recurrent B-cell non-Hodgkin lymphomas; the study i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy [Phase 2]
This clinical trial update indicates that Itacitinib is being studied as pre-modulation therapy in patients with diffuse large B-cell lympho…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant [Phase 2]
This Phase 2 clinical trial from Washington University School of Medicine is evaluating thiotepa-based autologous stem cell transplantation …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL [Phase 2]
Phase 2 single-arm trial evaluating ablative bridging irradiation before CD19 CAR-T therapy in high-risk relapsed/refractory large B-cell ly…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) [Phase 3]
This clinical trial update describes ACE-LY-312, a Phase 3 study evaluating acalabrutinib in combination with R-CHOP for previously untreate…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating first-line Tafasitamab, Polatuzumab Vedotin, and Glofitamab for diffuse large B-cell lymphoma and high-grade B-cell…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]
Phase 1 trial evaluating autologous CD22 CAR T cells in adults with recurrent or refractory B-cell malignancies has completed enrollment. Re…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation [Phase 2]
Phase 2 clinical trial evaluating a genetic subtype-matched targeted therapy for newly diagnosed Diffuse Large B-Cell Lymphoma with TP53 mut…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]
Clinical trial update for NexCAR19 (Talikabtagene autoleucel), a CAR-T therapy studied in relapsed/refractory B-cell malignancies; the Phase…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study evaluating Maplirpacept and Glofitamab together in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL [Phase 2]
This entry describes a Phase 2 trial comparing celecoxib added to R-CHOP versus R-CHOP alone in newly diagnosed CD5-positive diffuse large B…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 trial evaluating a four-drug regimen (romidepsin, gemcitabine, dexamethasone, cisplatin) in peripheral T-cell lymphoma and diffuse l…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation [Phase 2]
A Phase 2 clinical trial evaluates axicabtagene ciloleucel as second-line therapy for relapsed/refractory aggressive B-cell lymphoma in pati…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Glofitamab in Chinese Patients With R/R DLBCL
Clinical trial update for glofitamab in Chinese patients with relapsed/refractory diffuse large B-cell lymphoma; the study is currently recr…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Gut Microbiome in DLBCL Treated With Glofitamab
Clinical trial update examining the gut microbiome in patients with diffuse large B-cell lymphoma treated with glofitamab; the study status …
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib [Phase 2]
A Phase 2 trial evaluated the Bruton tyrosine kinase inhibitor zanubrutinib in CD79B-mutant relapsed/refractory diffuse large B-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study [Phase 2]
A Phase 2 prospective trial from Zhejiang Cancer Hospital reports that intrathecal TT (IT-TT) appears to be an effective and well-tolerated …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL [Phase 2]
A Phase 2 trial is evaluating chidamide in combination with R-mini CHOP followed by chidamide plus CD20 maintenance in elderly patients with…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP [Phase 3]
An ongoing Phase 3 trial evaluating chidamide as maintenance therapy for HBV-infected diffuse large B-cell lymphoma after R-CHOP is currentl…